HomeAI · summaries
Storia in 4 fonti
Exclusive: Bausch + Lomb plans Ph3 trial for dry eye drop, despite missing mid-stage goal
Bausch+Lomb's Xiidra/Miebo combo drop missed Phase 2 primary endpoint but CEO Brent Saunders calls it positive; Phase 3 planned with FDA's 15-day readout approval.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Exclusive: Bausch + Lomb plans Ph3 trial for dry eye drop, despite missing mid-stage goal
Bausch+Lomb's Xiidra/Miebo combo drop missed Phase 2 primary endpoint but CEO Brent Saunders calls it positive; Phase 3 planned with FDA's 15-day readout approval.
- ·
morningstar.com
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
